MCL stands for mantle cell lymphoma, a relatively uncommon B-cell non-Hodgkin lymphoma that often behaves aggressively and presents in advanced stage. It originates from the mantle zone of lymphoid follicles.
New market reports forecast significant expansion in CAR T-cell therapy, US pharmaceutical drug delivery, and healthcare nanotechnology sectors, driven by chronic disease prevalence and technological advances.
Recent studies demonstrate zanubrutinib delivers higher response rates, longer treatment persistence, and lower healthcare costs compared to acalabrutinib and ibrutinib across multiple B-cell malignancies, with particularly strong benefits in high-risk populations.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07460362 |
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma |
RECRUITING | PHASE2 |
| NCT07259070 |
Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma |
RECRUITING | PHASE1/PHASE2 |
| NCT07257055 |
Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study |
RECRUITING | PHASE2 |
| NCT06767891 |
Real-world Study of Acalabrutinib |
ENROLLING_BY_INVITATION | |
| NCT06463691 |
Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients |
RECRUITING | PHASE2 |
| NCT06213636 |
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). |
RECRUITING | PHASE1/PHASE2 |
| NCT06192888 |
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT05788289 |
A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma |
TERMINATED | PHASE2 |
| NCT05414162 |
Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy |
RECRUITING | |
| NCT05214183 |
Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma |
ACTIVE_NOT_RECRUITING | PHASE2 |
